ZBB Considered Useless By NCI Staff (Privately)’ New Approach Groups Program Into Four Categories
In Brief: Upton Okays Laetrile Clinical Trials, To Seek Protocols From Clinicians For IND Request
Regulatory Agencies Get Data For Action Against One Of World’s Most Widely Used Carcinogens
Change In Method Of Counting Cancer Incidence Results In More Attributed To Work Hazards
IG Report Clears Shubik Of Conflict Of Interest Change
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Trump targets HHS in $810M appropriations clawback
- Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?









